Factor IX Antibody (133-09): sc-59501
- Factor IX Antibody (133-09) is a mouse monoclonal IgG1 provided at 100 µg/ml
- raised against full length native Factor IX of human origin
- recommended for detection of native Factor IX of human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Factor IX Antibody (133-09). This work is in progress.
QUICK LINKS
SEE ALSO...
Factor IX Antibody (133-09) is a mouse monoclonal IgG1 antibody that detects coagulation factor IX in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Factor IX, also known as plasma thromboplastic component, plays a crucial role in the blood coagulation cascade, which is essential for hemostasis following tissue injury. Anti-Factor IX antibody (133-09) recognizes this vitamin K-dependent serine protease, which is synthesized in the liver and circulates as an inactive precursor until activated by factor XIa-mediated proteolytic cleavage, resulting in factor IXa. The active form consists of a 145 amino acid light chain and a 236 amino acid catalytic heavy chain, linked by disulfide bonds, which is vital for its enzymatic function in converting factor X to Xa, ultimately leading to the formation of fibrin clots. The importance of factor IX is underscored by its association with hemophilia B, a genetic disorder caused by mutations at the Factor IX locus, which can result in severe bleeding complications. Factor IX monoclonal antibody (133-09) serves as an invaluable tool for researchers studying coagulation pathways and related disorders, providing insights into the mechanisms of blood clotting and potential therapeutic targets.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Factor IX Antibody (133-09) References:
- Propagating factor IX-producing hepatocytes for haemophilia B therapy. | Ofosu, FA. 2008. Thromb Haemost. 99: 799-800. PMID: 18449406
- Activation mechanisms of coagulation factor IX. | Zögg, T. and Brandstetter, H. 2009. Biol Chem. 390: 391-400. PMID: 19361276
- Therapeutic properties and safety of recombinant factor VIII and factor IX. | Zdziarska, J., et al. 2009. Pol Arch Med Wewn. 119: 403-9. PMID: 19694223
- The mechanism underlying activation of factor IX by factor XIa. | Gailani, D., et al. 2014. Thromb Res. 133 Suppl 1: S48-51. PMID: 24759143
- Factor VIII/factor IX prophylaxis for severe hemophilia. | Carcao, M. and Srivastava, A. 2016. Semin Hematol. 53: 3-9. PMID: 26805901
- Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption. | Iorio, A., et al. 2017. J Med Econ. 20: 337-344. PMID: 27885871
- GlycoPEGylated recombinant factor IX for hemophilia B in context. | Santagostino, E. and Mancuso, ME. 2018. Drug Des Devel Ther. 12: 2933-2943. PMID: 30254423
- Characterisation of recombinant factor IX before and after GlycoPEGylation. | Nielsen, FS., et al. 2020. Int J Pharm. 588: 119654. PMID: 32693290
- The Function of extravascular coagulation factor IX in haemostasis. | Mann, DM., et al. 2021. Haemophilia. 27: 332-339. PMID: 33780107
- Extravascular Binding of Coagulation Factor IX Gives Hemostasis a Boost. | Pilch, J. and Knowles, LM. 2023. Thromb Haemost. 123: 750. PMID: 37011897
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Factor IX Antibody (133-09) | sc-59501 | 100 µg/ml | $316.00 |